Abstract

Joanny, P., J. Steinberg, C. Oliver and M. Grino.Effect of excitatory amino acids on rat hypothalamic somatostatin secretion in vitro.PEPTIDES 18(7) 1039–1043, 1997.—We studied the effect of various agonists of excitatory amino acid (EAA) receptor subtypes on somatostatin (SRIF) release from incubated rat hypothalamic slices. N-Methyl-d-aspartic acid (NMDA) and l-glutamate (1 × 10−7 to 1 × 10−3M) stimulated, in a dose-dependent fashion, SRIF release. The maximal effect was obtained at a concentration of 1 × 10−4M for both drugs. The IC50 was 3.2 × 10−5M and 2.1 × 10−5M for NMDA and l-glutamate, respectively. Incubation with 2.5 × 10−4Md-2-amino-5-phosphonovalerate (a NMDA receptor antagonist) or 2-amino-4-phosphonobutyrate (a metabotropic receptor antagonist) was without significant effect on basal SRIF secretion and completely blocked the increase in SRIF release induced by 5 × 10−5M NMDA or l-glutamate, respectively. Incubation with 1 × 10−4M kainate or 0.5 × 10−4M α-amino-3-hydroxy-5-methyl-4-isoxazolepropionate (AMPA) did not change basal SRIF secretion. Incubation with 2 × 10−4M γ-d-glutamylglycine (a specific antagonist of kainate and AMPA receptors) had no effect under basal conditions or during exposure to kainate or AMPA. Our data demonstrate that EAAs stimulate SRIF secretion in vitro, by an action through NMDA and metabotropic receptors but not kainate or AMPA receptors.

Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.